Vimarsana
Biggest News Aggregation in the World

Page 13 - Clinical Modification News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Modification. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Modification Today - Breaking & Trending Today

Pharming Group reports financial results for full year 2022 - Vimarsana News

Pharming Group reports financial results for full year 2022

/PRNewswire/ -- Total revenues increased by 3% to US$205.6 million, in line with single digit growth guidance Operating profit increased by 34% to US$18.2...

No increased risk of neuropsychiatric events in children born to mothers using leukotriene-receptor antagonists in pregnancy - Vimarsana News

No increased risk of neuropsychiatric events in children born to mothers using leukotriene-receptor antagonists in pregnancy

A new study examined the associations between leukotriene-receptor antagonists (LTRAs) use in pregnancy and neuropsychiatric events (NEs) risk in the offspring.

Cigarette Smoking Identified as Risk Factor for Postmenopausal Psoriasis - Vimarsana News

Cigarette Smoking Identified as Risk Factor for Postmenopausal Psoriasis

Study finds that cigarette smoking and not alcohol consumption is associated with an increased risk for psoriasis among postmenopausal women.

The Federal Government Is Tracking the Unvaccinated - Vimarsana News

The Federal Government Is Tracking the Unvaccinated

The U.S. government has been secretly tracking those who didn't get the COVID jab, as well as those ...

Vaccine efficacy and booster dose combinations among 18.9 million adults in the early phase of Omicron - Vimarsana News

Vaccine efficacy and booster dose combinations among 18.9 million adults in the early phase of Omicron

A new study in the journal Clinical Infectious Diseases aimed to determine the relative vaccine effectiveness (rVE) in three different recipient cohorts, those who received the Ad26.COV2.S vaccine followed by Ad26.COV2.S booster, those who received the Ad26.COV2.S vaccine followed by an mRNA booster, and those who received two doses of an mRNA vaccine followed by an mRNA booster.